Related Experiment Videos
Development of COX inhibitors in cancer prevention and therapy
Asad Umar1, Jaye L Viner, William F Anderson
1Gastrointestinal & Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892-7317, USA.
Abstract:
On the strength of in vitro, in vivo, observational, and clinical data, nonsteroidal antiinflammatory drugs (NSAIDs)-also referred to as COX inhibitors-have emerged as lead compounds for cancer prevention, and possible adjuncts to cancer therapy. Thus far, the routine use of NSAIDs for these indications is limited, largely owing to toxicity concerns, the paucity of efficacy data for any specific target organ, and uncertainties with regard to the most appropriate regimen (i.e., the best agent, formulation, dose, route of administration, and duration). Strategies to address these concerns primarily aim to improve the therapeutic index (i.e., benefit:risk ratio) of COX inhibitors by 1) minimizing systemic exposures whenever feasible, 2) achieving greater mechanistic specificity, 3) coadministering agents that provide prophylaxis against common toxicities, and 4) coadministering other effective anticancer agents. Clinical trials testing most of these strategies have been completed or are under way. The National Cancer Institute has a substantial research portfolio dedicated to the identification, testing, and development of NSAIDs as preventive and therapeutic anticancer agents. Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) show promise for cancer prevention and therapy. However, toxicity and efficacy uncertainties limit their use, prompting research into improved strategies for better benefit-risk ratios.
Area of Science:
- Oncology
- Pharmacology
- Preventive Medicine
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs), also known as COX inhibitors, have demonstrated potential in cancer prevention and as adjuncts in cancer therapy based on extensive research.
- Current clinical use of NSAIDs for cancer indications is restricted due to concerns regarding toxicity, limited organ-specific efficacy data, and undefined optimal treatment regimens.
Purpose of the Study:
- To explore the potential of NSAIDs as anticancer agents for both prevention and therapy.
- To address the limitations hindering the routine use of NSAIDs in oncology, focusing on improving their therapeutic index.
Main Methods:
- Review and synthesis of in vitro, in vivo, observational, and clinical data.
- Evaluation of strategies to enhance the benefit:risk ratio of COX inhibitors, including minimizing systemic exposure, increasing mechanistic specificity, and co-administration with prophylactic or anticancer agents.
- Monitoring of ongoing and completed clinical trials investigating these strategies.
Main Results:
- NSAIDs are recognized as lead compounds for cancer prevention and potential therapeutic adjuncts.
- Strategies to improve NSAID therapeutic index are under active investigation through clinical trials.
- The National Cancer Institute actively supports research and development of NSAIDs for cancer applications.
Conclusions:
- Despite challenges, optimizing NSAID application in cancer patients or those at risk holds significant potential for clinical and public health benefits.
- Further research and clinical trials are crucial to overcome toxicity and efficacy concerns, paving the way for wider NSAID use in oncology.